In chronic kidney disease (CKD), the kidneys often produce less erythropoietin, a hormone essential for red blood cell production. This can lead to anemia, a condition characterized by a deficiency of red blood cells or hemoglobin. The optimal concentration of hemoglobin for individuals with this condition is a subject of ongoing clinical research and practice guidelines. Maintaining an appropriate level aims to alleviate anemia-related symptoms, such as fatigue and shortness of breath, while minimizing potential risks.
Balancing the benefits and risks associated with different hemoglobin levels is a critical aspect of CKD management. Historically, higher concentrations were targeted, but more recent research suggests that this approach may be associated with adverse cardiovascular outcomes. Therefore, current clinical practice guidelines generally recommend a more conservative approach, individualizing the desired level based on the patient’s specific circumstances, comorbidities, and response to treatment.
